Peipei Wu
Research Subjects
Peipei Wu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Hui Qian
Jiangsu University 301 Xuefu Road
7 shared publications - Jiali Li
Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University , Zhenjiang 212013
3 shared publications - Jiaxin Zhang
Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University , Zhenjiang 212013
3 shared publications - Wenrong Xu
Aoyang Institute of Cancer, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, China
3 shared publications - Zixuan Sun
Jiangsu University
3 shared publications - Hui Shi
Department of Orthopedics, Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, Suzhou, China
2 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41)
GDNF‐Enriched Small Extracellular Vesicle‐Loaded ROS‐Scavenging Hydrogel Promotes Neural Regeneration After Spinal Cord Injury
Spinal cord injury (SCI) is a severe traumatic disorder of the central nervous system that results in substantial motor and sensory dysfunction. The hostile post‐injury microenvironment, marked by excessive oxidative stress, inflammatory responses, and progressive neuronal degeneration, greatly limits neural repair. In this study, we developed a multifunctional reactive oxygen species (ROS)‐scavenging hydrogel composed of N‐acryloylglycylamide (NAGA), xanthan gum (XG), carbomer 940 (CBP940), and tannic acid (TA) (termed NXCT) to locally deliver glial cell line‐derived neurotrophic factor (GDNF)‐enriched small extracellular vesicles (sEVs). GDNF, as a key neurotrophic protein, was incorporated into engineered sEVs to enhance their neuroregenerative activity. The resulting GDNF‐sEVs@NXCT hydrogel exhibited favorable antioxidant and anti‐inflammatory properties in vitro and effectively supported neuronal survival and axonal regeneration. After in situ implantation into the injured spinal cord, GDNF‐sEVs@NXCT reduced ROS accumulation, alleviated inflammatory responses, promoted neural and myelin regeneration, and enhanced motor functional recovery in SCI rats. RNA‐sequencing further uncovered that these therapeutic effects of GDNF‐sEVs@NXCT were associated with PI3K/AKT pathway activation. Overall, these results demonstrate that the GDNF‐sEVs@NXCT hydrogel provides a bioactive macromolecule‐based therapeutic strategy for SCI repair via microenvironment modulation and neuroregeneration, highlighting its translational potential for spinal cord repair.
- 5 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41)
Open AccessGDNF‐Enriched Small Extracellular Vesicle‐Loaded ROS‐Scavenging Hydrogel Promotes Neural Regeneration After Spinal Cord Injury
Spinal cord injury (SCI) is a severe traumatic disorder of the central nervous system that results in substantial motor and sensory dysfunction. The hostile post‐injury microenvironment, marked by excessive oxidative stress, inflammatory responses, and progressive neuronal degeneration, greatly limits neural repair. In this study, we developed a multifunctional reactive oxygen species (ROS)‐scavenging hydrogel composed of N‐acryloylglycylamide (NAGA), xanthan gum (XG), carbomer 940 (CBP940), and tannic acid (TA) (termed NXCT) to locally deliver glial cell line‐derived neurotrophic factor (GDNF)‐enriched small extracellular vesicles (sEVs). GDNF, as a key neurotrophic protein, was incorporated into engineered sEVs to enhance their neuroregenerative activity. The resulting GDNF‐sEVs@NXCT hydrogel exhibited favorable antioxidant and anti‐inflammatory properties in vitro and effectively supported neuronal survival and axonal regeneration. After in situ implantation into the injured spinal cord, GDNF‐sEVs@NXCT reduced ROS accumulation, alleviated inflammatory responses, promoted neural and myelin regeneration, and enhanced motor functional recovery in SCI rats. RNA‐sequencing further uncovered that these therapeutic effects of GDNF‐sEVs@NXCT were associated with PI3K/AKT pathway activation. Overall, these results demonstrate that the GDNF‐sEVs@NXCT hydrogel provides a bioactive macromolecule‐based therapeutic strategy for SCI repair via microenvironment modulation and neuroregeneration, highlighting its translational potential for spinal cord repair.
- Open Access
- 19 October 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (11) , 1129-1143
Mesenchymal stromal cells-derived small extracellular vesicles protect against UV-induced photoaging via regulating pregnancy zone protein
Ultraviolet (UV) radiation is the primary extrinsic factor in skin aging, contributing to skin photoaging, actinic keratosis (AK), and even squamous cell carcinoma (SCC). Currently, the beneficial role of mesenchymal stromal cell-derived small extracellular vesicles (MSC-sEVs) in cutaneous wound healing has been widely reported, but the field of photoaging remains to be explored. Our results suggested that human umbilical cord MSC-derived sEVs (hucMSC-sEVs) intervention could effectively alleviate skin photoaging phenotypes in vivo and in vitro, including ameliorating UV-induced histopathological changes in the skin and inhibiting oxidative stress and collagen degradation in dermal fibroblasts (DFs). Mechanistically, pretreatment with hucMSC-sEVs reversed UVA-induced down-regulation of pregnancy zone protein (PZP) in DFs, and achieved photoprotection by inhibiting matrix metalloproteinase-1 (MMP-1) expression and reducing DNA damage. Clinically, a significant decrease in PZP in AK and SCC in situ samples was observed, while a rebound appeared in the invasive SCC samples. Collectively, our findings reveal the effective role of hucMSC-sEVs in regulating PZP to combat photoaging and provide new pre-clinical evidence for the potential development of hucMSC-sEVs as an effective skin photoprotective agent.
- 19 October 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (11) , 1129-1143
Open AccessMesenchymal stromal cells-derived small extracellular vesicles protect against UV-induced photoaging via regulating pregnancy zone protein
Ultraviolet (UV) radiation is the primary extrinsic factor in skin aging, contributing to skin photoaging, actinic keratosis (AK), and even squamous cell carcinoma (SCC). Currently, the beneficial role of mesenchymal stromal cell-derived small extracellular vesicles (MSC-sEVs) in cutaneous wound healing has been widely reported, but the field of photoaging remains to be explored. Our results suggested that human umbilical cord MSC-derived sEVs (hucMSC-sEVs) intervention could effectively alleviate skin photoaging phenotypes in vivo and in vitro, including ameliorating UV-induced histopathological changes in the skin and inhibiting oxidative stress and collagen degradation in dermal fibroblasts (DFs). Mechanistically, pretreatment with hucMSC-sEVs reversed UVA-induced down-regulation of pregnancy zone protein (PZP) in DFs, and achieved photoprotection by inhibiting matrix metalloproteinase-1 (MMP-1) expression and reducing DNA damage. Clinically, a significant decrease in PZP in AK and SCC in situ samples was observed, while a rebound appeared in the invasive SCC samples. Collectively, our findings reveal the effective role of hucMSC-sEVs in regulating PZP to combat photoaging and provide new pre-clinical evidence for the potential development of hucMSC-sEVs as an effective skin photoprotective agent.
- Open Access
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28
Highly Efficient Delivery of Novel MiR-13896 by Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Inhibits Gastric Cancer Progression by Targeting ATG2A-Mediated Autophagy
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. Despite recent advancements, clinical outcomes for GC remain unsatisfactory. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have shown promise in inhibiting tumor progression, but their role in GC, specifically human umbilical cord MSC-derived small EVs (hucMSC-sEVs), is not well understood. This study investigates the therapeutic potential of hucMSC-sEVs in GC treatment. We found that hucMSC-sEVs are captured by GC cells, substantially inhibiting their proliferation and inducing apoptosis. MiRNA sequencing revealed that hucMSC-sEVs were enriched with miRNAs having anticancer properties. Among these, miR-13896, a new miRNA, was identified as a potent inhibitor of GC cell proliferation and a promoter of apoptosis. Mechanistic studies revealed that miR-13896 targets and down-regulates the ATG2A-mediated autophagy pathway, suppressing GC cell growth and metastasis. Furthermore, we enriched hucMSC-sEVs with miR-13896 through electroporation. These engineered EVs specifically targeted tumor sites and significantly reduced GC cell growth and migration in vitro and in vivo. MiR-13896 emerged as a promising therapeutic target for GC. The delivery of miR-13896 via hucMSC-sEVs represents a novel and effective strategy for GC treatment, highlighting the potential of EV-based therapies to combat this malignancy.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28
Open AccessHighly Efficient Delivery of Novel MiR-13896 by Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Inhibits Gastric Cancer Progression by Targeting ATG2A-Mediated Autophagy
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. Despite recent advancements, clinical outcomes for GC remain unsatisfactory. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have shown promise in inhibiting tumor progression, but their role in GC, specifically human umbilical cord MSC-derived small EVs (hucMSC-sEVs), is not well understood. This study investigates the therapeutic potential of hucMSC-sEVs in GC treatment. We found that hucMSC-sEVs are captured by GC cells, substantially inhibiting their proliferation and inducing apoptosis. MiRNA sequencing revealed that hucMSC-sEVs were enriched with miRNAs having anticancer properties. Among these, miR-13896, a new miRNA, was identified as a potent inhibitor of GC cell proliferation and a promoter of apoptosis. Mechanistic studies revealed that miR-13896 targets and down-regulates the ATG2A-mediated autophagy pathway, suppressing GC cell growth and metastasis. Furthermore, we enriched hucMSC-sEVs with miR-13896 through electroporation. These engineered EVs specifically targeted tumor sites and significantly reduced GC cell growth and migration in vitro and in vivo. MiR-13896 emerged as a promising therapeutic target for GC. The delivery of miR-13896 via hucMSC-sEVs represents a novel and effective strategy for GC treatment, highlighting the potential of EV-based therapies to combat this malignancy.
- Open Access
- 8 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6742792
Diagnostic and Therapeutic Roles of Extracellular Vesicles in Aging‐Related Diseases
Aging shows a decline in overall physical function, and cellular senescence is the powerful catalyst leading to aging. Considering that aging will be accompanied with the emergence of various aging‐related diseases, research on new antiaging drugs is still valuable. Extracellular vesicles (EVs), as tools for intercellular communication, are important components of the senescence‐associated secretory phenotype (SASP), and they can play pathological roles in the process of cellular senescence. In addition, EVs are similar to their original cells in functions. Therefore, EVs derived from pathological tissues or body fluids may be closely related to the progression of diseases and become potential biomarkers, while those from healthy cells may have therapeutic effects. Moreover, EVs are satisfactory drug carriers. At present, numerous studies have supported the idea that engineered EVs could improve drug targeting ability and utilization efficiency. Here, we summarize the characteristics of EVs and cellular senescence and focus on the diagnostic and therapeutic potential of EVs in various aging‐related diseases, including Alzheimer disease, osteoporosis, cardiovascular disease, diabetes mellitus and its complications, and skin aging.
- 8 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6742792
Open AccessDiagnostic and Therapeutic Roles of Extracellular Vesicles in Aging‐Related Diseases
Aging shows a decline in overall physical function, and cellular senescence is the powerful catalyst leading to aging. Considering that aging will be accompanied with the emergence of various aging‐related diseases, research on new antiaging drugs is still valuable. Extracellular vesicles (EVs), as tools for intercellular communication, are important components of the senescence‐associated secretory phenotype (SASP), and they can play pathological roles in the process of cellular senescence. In addition, EVs are similar to their original cells in functions. Therefore, EVs derived from pathological tissues or body fluids may be closely related to the progression of diseases and become potential biomarkers, while those from healthy cells may have therapeutic effects. Moreover, EVs are satisfactory drug carriers. At present, numerous studies have supported the idea that engineered EVs could improve drug targeting ability and utilization efficiency. Here, we summarize the characteristics of EVs and cellular senescence and focus on the diagnostic and therapeutic potential of EVs in various aging‐related diseases, including Alzheimer disease, osteoporosis, cardiovascular disease, diabetes mellitus and its complications, and skin aging.
- Open Access
- 29 July 2022
- Published by Wiley in Stem Cells International
- Vol. 2022, 1-27
Tailored Extracellular Vesicles: Novel Tool for Tissue Regeneration
Extracellular vesicles (EVs) play an essential part in multiple pathophysiological processes including tissue injury and regeneration because of their inherent characteristics of small size, low immunogenicity and toxicity, and capability of carrying a variety of bioactive molecules and mediating intercellular communication. Nevertheless, accumulating studies have shown that the application of EVs faces many challenges such as insufficient therapeutic efficacy, a lack of targeting capability, low yield, and rapid clearance from the body. It is known that EVs can be engineered, modified, and designed to encapsulate therapeutic cargos like proteins, peptides, nucleic acids, and drugs to improve their therapeutic efficacy. Targeted peptides, antibodies, aptamers, magnetic nanoparticles, and proteins are introduced to modify various cell-derived EVs for increasing targeting ability. In addition, extracellular vesicle mimetics (EMs) and self-assembly EV-mimicking nanocomplex are applied to improve production and simplify EV purification process. The combination of EVs with biomaterials like hydrogel, and scaffolds dressing endows EVs with long-term therapeutic efficacy and synergistically enhanced regenerative outcome. Thus, we will summarize recent developments of EV modification strategies for more extraordinary regenerative effect in various tissue injury repair. Subsequently, opportunities and challenges of promoting the clinical application of engineered EVs will be discussed.
- 29 July 2022
- Published by Wiley in Stem Cells International
- Vol. 2022, 1-27
Open AccessTailored Extracellular Vesicles: Novel Tool for Tissue Regeneration
Extracellular vesicles (EVs) play an essential part in multiple pathophysiological processes including tissue injury and regeneration because of their inherent characteristics of small size, low immunogenicity and toxicity, and capability of carrying a variety of bioactive molecules and mediating intercellular communication. Nevertheless, accumulating studies have shown that the application of EVs faces many challenges such as insufficient therapeutic efficacy, a lack of targeting capability, low yield, and rapid clearance from the body. It is known that EVs can be engineered, modified, and designed to encapsulate therapeutic cargos like proteins, peptides, nucleic acids, and drugs to improve their therapeutic efficacy. Targeted peptides, antibodies, aptamers, magnetic nanoparticles, and proteins are introduced to modify various cell-derived EVs for increasing targeting ability. In addition, extracellular vesicle mimetics (EMs) and self-assembly EV-mimicking nanocomplex are applied to improve production and simplify EV purification process. The combination of EVs with biomaterials like hydrogel, and scaffolds dressing endows EVs with long-term therapeutic efficacy and synergistically enhanced regenerative outcome. Thus, we will summarize recent developments of EV modification strategies for more extraordinary regenerative effect in various tissue injury repair. Subsequently, opportunities and challenges of promoting the clinical application of engineered EVs will be discussed.
- Open Access
- 21 August 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-18
Exosomes: Emerging Therapy Delivery Tools and Biomarkers for Kidney Diseases
Exosomes are nanometer-sized small EVs coated with bilayer structure, which are released by prokaryotic and eukaryotic cells. Exosomes are rich in a variety of biologically active substances, such as proteins, nucleotides, and lipids. Exosomes are widely present in various body fluids and cell culture supernatants, and it mediates the physiological and pathological processes of the body through the shuttle of these active ingredients to target cells. In recent years, studies have shown that exosomes from a variety of cell sources can play a beneficial role in acute and chronic kidney disease. In particular, exosomes derived from mesenchymal stem cells have significant curative effects on the prevention and treatment of kidney disease in preclinical trials. Besides, some encapsulated substances are demonstrated to exert beneficial effects on various diseases, so they have attracted much attention. In addition, exosomes have extensive sources, stable biological activity, and good biocompatibility and are easy to store and transport; these advantages endow exosomes with superior diagnostic value. With the rapid development of liquid biopsy technology related to exosomes, the application of exosomes in the rapid diagnosis of kidney disease has become more prominent. In this review, the latest development of exosomes, including the biosynthesis process, the isolation and identification methods of exosomes are systematically summarized. The utilization of exosomes in diagnosis and their positive effects in the repair of kidney dysfunction are discussed, along with the specific mechanisms. This review is expected to be helpful for relevant studies and to provide insight into future applications in clinical practice.
- 21 August 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-18
Open AccessExosomes: Emerging Therapy Delivery Tools and Biomarkers for Kidney Diseases
Exosomes are nanometer-sized small EVs coated with bilayer structure, which are released by prokaryotic and eukaryotic cells. Exosomes are rich in a variety of biologically active substances, such as proteins, nucleotides, and lipids. Exosomes are widely present in various body fluids and cell culture supernatants, and it mediates the physiological and pathological processes of the body through the shuttle of these active ingredients to target cells. In recent years, studies have shown that exosomes from a variety of cell sources can play a beneficial role in acute and chronic kidney disease. In particular, exosomes derived from mesenchymal stem cells have significant curative effects on the prevention and treatment of kidney disease in preclinical trials. Besides, some encapsulated substances are demonstrated to exert beneficial effects on various diseases, so they have attracted much attention. In addition, exosomes have extensive sources, stable biological activity, and good biocompatibility and are easy to store and transport; these advantages endow exosomes with superior diagnostic value. With the rapid development of liquid biopsy technology related to exosomes, the application of exosomes in the rapid diagnosis of kidney disease has become more prominent. In this review, the latest development of exosomes, including the biosynthesis process, the isolation and identification methods of exosomes are systematically summarized. The utilization of exosomes in diagnosis and their positive effects in the repair of kidney dysfunction are discussed, along with the specific mechanisms. This review is expected to be helpful for relevant studies and to provide insight into future applications in clinical practice.
- Open Access
- 10 July 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-10
Roles of Mesenchymal Stem Cell-Derived Exosomes in Cancer Development and Targeted Therapy
Exosomes have emerged as a new drug delivery system. In particular, exosomes derived from mesenchymal stem cells (MSCs) have been extensively studied because of their tumor-homing ability and yield advantages. Considering that MSC-derived exosomes are a double-edged sword in the development, metastasis, and invasion of tumors, engineered exosomes have broad potential use. In this review, we focused on the latest development in the treatment of tumors using engineered and nonengineered MSC-derived exosomes (MSC-EXs). Nonengineered MSC-EXs exert an antitumor effect on several well-studied tumors by affecting tumor growth, angiogenesis, metastasis, and invasion. Furthermore, engineered exosomes have promising research prospects as drug-carrying tools for the transport of miRNAs, small-molecule drugs, and proteins. Although exosomes lack uniform standards in terms of definition, separation, and purification, they still have great research value because of their unique advantages, such as high biocompatibility and low toxicity. Future studies on MSC-EXs should elucidate the mechanisms underlying their anticancer effect and the safety of their application.
- 10 July 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-10
Open AccessRoles of Mesenchymal Stem Cell-Derived Exosomes in Cancer Development and Targeted Therapy
Exosomes have emerged as a new drug delivery system. In particular, exosomes derived from mesenchymal stem cells (MSCs) have been extensively studied because of their tumor-homing ability and yield advantages. Considering that MSC-derived exosomes are a double-edged sword in the development, metastasis, and invasion of tumors, engineered exosomes have broad potential use. In this review, we focused on the latest development in the treatment of tumors using engineered and nonengineered MSC-derived exosomes (MSC-EXs). Nonengineered MSC-EXs exert an antitumor effect on several well-studied tumors by affecting tumor growth, angiogenesis, metastasis, and invasion. Furthermore, engineered exosomes have promising research prospects as drug-carrying tools for the transport of miRNAs, small-molecule drugs, and proteins. Although exosomes lack uniform standards in terms of definition, separation, and purification, they still have great research value because of their unique advantages, such as high biocompatibility and low toxicity. Future studies on MSC-EXs should elucidate the mechanisms underlying their anticancer effect and the safety of their application.
- 23 February 2015
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 59 (3) , 338-345
Intra‐tumour 18F‐FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging
Introduction: This study aims to explore whether the intra‐tumour 18F‐fluorodeoxyglucose (FDG) uptake heterogeneity affects the reliability of target volume definition with FDG positron emission tomography/computed tomography (PET/CT) imaging for nonsmall cell lung cancer (NSCLC) and squamous cell oesophageal cancer (SCEC).Methods: Patients with NSCLC (n = 50) or SCEC (n = 50) who received 18F‐FDG PET/CT scanning before treatments were included in this retrospective study. Intra‐tumour FDG uptake heterogeneity was assessed by visual scoring, the coefficient of variation (COV) of the standardised uptake value (SUV) and the image texture feature (entropy). Tumour volumes (gross tumour volume (GTV) ) were delineated on the CT images (GTVCT), the fused PET/CT images (GTVPET‐CT) and the PET images, using a threshold at 40% SUVmax (GTVPET40%) or the SUV cut‐off value of 2.5 (GTVPET2.5). The correlation between the FDG uptake heterogeneity parameters and the differences in tumour volumes among GTVCT, GTVPET‐CT, GTVPET40% and GTVPET2.5 was analysed.Results: For both NSCLC and SCEC, obvious correlations were found between uptake heterogeneity, SUV or tumour volumes. Three types of heterogeneity parameters were consistent and closely related to each other. Substantial differences between the four methods of GTV definition were found. The differences between the GTV correlated significantly with PET heterogeneity defined with the visual score, the COV or the textural feature‐entropy for NSCLC and SCEC.Conclusions: In tumours with a high FDG uptake heterogeneity, a larger GTV delineation difference was found. Advance image segmentation algorithms dealing with tracer uptake heterogeneity should be incorporated into the treatment planning system.
- 23 February 2015
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 59 (3) , 338-345
Intra‐tumour 18F‐FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging
Introduction: This study aims to explore whether the intra‐tumour 18F‐fluorodeoxyglucose (FDG) uptake heterogeneity affects the reliability of target volume definition with FDG positron emission tomography/computed tomography (PET/CT) imaging for nonsmall cell lung cancer (NSCLC) and squamous cell oesophageal cancer (SCEC).Methods: Patients with NSCLC (n = 50) or SCEC (n = 50) who received 18F‐FDG PET/CT scanning before treatments were included in this retrospective study. Intra‐tumour FDG uptake heterogeneity was assessed by visual scoring, the coefficient of variation (COV) of the standardised uptake value (SUV) and the image texture feature (entropy). Tumour volumes (gross tumour volume (GTV) ) were delineated on the CT images (GTVCT), the fused PET/CT images (GTVPET‐CT) and the PET images, using a threshold at 40% SUVmax (GTVPET40%) or the SUV cut‐off value of 2.5 (GTVPET2.5). The correlation between the FDG uptake heterogeneity parameters and the differences in tumour volumes among GTVCT, GTVPET‐CT, GTVPET40% and GTVPET2.5 was analysed.Results: For both NSCLC and SCEC, obvious correlations were found between uptake heterogeneity, SUV or tumour volumes. Three types of heterogeneity parameters were consistent and closely related to each other. Substantial differences between the four methods of GTV definition were found. The differences between the GTV correlated significantly with PET heterogeneity defined with the visual score, the COV or the textural feature‐entropy for NSCLC and SCEC.Conclusions: In tumours with a high FDG uptake heterogeneity, a larger GTV delineation difference was found. Advance image segmentation algorithms dealing with tracer uptake heterogeneity should be incorporated into the treatment planning system.